<DOC>
	<DOCNO>NCT02108210</DOCNO>
	<brief_summary>Rationale : Chronic fatigue syndrome ( CFS ) medically unexplained syndrome somatic pharmacological treatment proven effective . Dysfunction cytokine network suspect play role pathophysiology CFS . Although derangement cytokine network CFS controversial , major problem many study use adequate control . In addition , study perform peripheral venous blood patient . As cytokine mainly act tissue , e.g. , brain , information derive peripheral blood cell limit . The information regard possible role cytokine pathophysiology CFS could come intervention study pathogenetically important cytokine inhibit . A potentially relevant cytokine block human without severe side effect IL-1 . Although plausible cytokine play role CFS , limit evidence . Objective : To investigate effect symptomatology interference IL-1 CFS patient . Study design : A randomized placebo control study perform determine whether interference IL-1 able reduce fatigue disability CFS patient . Study population : Female CFS patient without psychiatric co-morbidity include study . Patients outpatient clinic Department General internal medicine Expert Centre Chronic Fatigue ( ECCF ) ask participate study . Patients ask bring healthy neighbourhood control first study visit . Intervention : After inclusion patient randomize receive one follow treatment : - interleukin-1 inhibitor Anakinra ( IL-1Ra ) 4 week ( N=25 ) ; - placebo 4 week ( N=25 ) . Main study parameters/endpoints : The primary outcome measure fatigue severity measure Checklist Individual Strength ( CIS ) 4 week , measurement repeat 26 week . Secondary outcome measure : - level functional impairment measure Sickness Impact Profile ( SIP8 ) total score ; - physical social functioning assessed subscale physical function social function SF-36 ; - level psychological distress assess total score Symptom Checklist-90 ( SCL-90 ) ; - pain severity assess Visual Analog Scale ( VAS ) ; - cytokine measurement blood ( plasma blood Pax-gene tube ) saliva ( protein mRNA level ) ; - cortisol measurement saliva hair ; - microbiome determination faeces ; - body temperature pulse rate .</brief_summary>
	<brief_title>Cytokine Inhibition Chronic Fatigue Syndrome Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Fatigue Syndrome , Chronic</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>CDCdiagnosed CFSpatients ; female , 18 59 year old ; fatigue duration ≤10 year , significant increase complaint last 10 year score ≥40 subscale fatigue severity CIS ( Checklist Individual Strength ) ; mark functional impairment assess Sickness Impact Profile ( SIP8 ) operationalised total score ≥700 . pregnant nursing woman ; woman intend get pregnant study ; fatigue duration &gt; 10 year ; patient use use psychotropic medication past month ; substance abuse past 3 month ; patient take medication except oral contraceptive and/or paracetamol ; patient evident somatic comorbidity ; previous current engagement CFS research ; inability understand nature extent trial procedure require ; psychiatric comorbidity ( major depression , psychosis , eat disorder , anxiety disorder , bipolar disease post traumatic stress disorder ) assess MINI ; live vaccination past four week ; current engagement legal procedure respect disability claim .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic fatigue syndrome</keyword>
	<keyword>Cytokines</keyword>
	<keyword>Interleukin-1</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Anakinra</keyword>
</DOC>